7UJ3

Crystal structure of Human respiratory syncytial virus F variant (construct pXCS847A)

7UJ3 の概要

• エントリーDOI: 10.2210/pdb7uj3/pdb
• 分子名称: RSV variant (construct pXCS847A) F2, RSV variant (construct pXCS847A) F1, SULFATE ION, ... (4 entities in total)
• 機能のキーワード: rsv, rsvf, pre-fusion, virus
• 由来する生物種: Respiratory syncytial virus; 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 57644.74

構造登録者

Han, S.,Ammirati, M. (登録日: 2022-03-30, 公開日: 2023-04-19, 最終更新日: 2024-11-06)

主引用文献

Che, Y.,Gribenko, A.V.,Song, X.,Handke, L.D.,Efferen, K.S.,Tompkins, K.,Kodali, S.,Nunez, L.,Prasad, A.K.,Phelan, L.M.,Ammirati, M.,Yu, X.,Lees, J.A.,Chen, W.,Martinez, L.,Roopchand, V.,Han, S.,Qiu, X.,DeVincenzo, J.P.,Jansen, K.U.,Dormitzer, P.R.,Swanson, K.A.
Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine.
Sci Transl Med, 15:eade6422-eade6422, 2023

PubMed Abstract: Respiratory syncytial virus (RSV) is the leading, global cause of serious respiratory disease in infants and is an important cause of respiratory illness in older adults. No RSV vaccine is currently available. The RSV fusion (F) glycoprotein is a key antigen for vaccine development, and its prefusion conformation is the target of the most potent neutralizing antibodies. Here, we describe a computational and experimental strategy for designing immunogens that enhance the conformational stability and immunogenicity of RSV prefusion F. We obtained an optimized vaccine antigen after screening nearly 400 engineered F constructs. Through in vitro and in vivo characterization studies, we identified F constructs that are more stable in the prefusion conformation and elicit ~10-fold higher serum-neutralizing titers in cotton rats than DS-Cav1. The stabilizing mutations of the lead construct (847) were introduced onto F glycoprotein backbones of strains representing the dominant circulating genotypes of the two major RSV subgroups, A and B. Immunization of cotton rats with a bivalent vaccine formulation of these antigens conferred complete protection against RSV challenge, with no evidence of disease enhancement. The resulting bivalent RSV prefusion F investigational vaccine has recently been shown to be efficacious against RSV disease in two pivotal phase 3 efficacy trials, one for passive protection of infants by immunization of pregnant women and the second for active protection of older adults by direct immunization.

PubMed: 37023209
DOI: 10.1126/scitranslmed.ade6422

実験手法

X-RAY DIFFRACTION (3.5 Å)